DK171988B1 - Kvaternære 8-(alkyldithio)-1-(2-pyrimidyl)quinoliniumsalte - Google Patents
Kvaternære 8-(alkyldithio)-1-(2-pyrimidyl)quinoliniumsalte Download PDFInfo
- Publication number
- DK171988B1 DK171988B1 DK354089D DK354089D DK171988B1 DK 171988 B1 DK171988 B1 DK 171988B1 DK 354089 D DK354089 D DK 354089D DK 354089 D DK354089 D DK 354089D DK 171988 B1 DK171988 B1 DK 171988B1
- Authority
- DK
- Denmark
- Prior art keywords
- pyrimidyl
- quaternary
- alkyl
- quinolinium salts
- compound according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 20
- 150000001450 anions Chemical class 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 abstract description 6
- 231100000397 ulcer Toxicity 0.000 abstract description 5
- 108091006112 ATPases Proteins 0.000 abstract description 4
- 102000057290 Adenosine Triphosphatases Human genes 0.000 abstract description 4
- 239000003112 inhibitor Substances 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 abstract description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-O hydron;quinoline Chemical class [NH+]1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-O 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 6
- 239000003699 antiulcer agent Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- -1 omeprazole Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- IWOYCTRGXAQCLW-UHFFFAOYSA-N 8-(4-ethoxypyrimidin-2-yl)sulfinylquinoline Chemical compound CCOC1=CC=NC(S(=O)C=2C3=NC=CC=C3C=CC=2)=N1 IWOYCTRGXAQCLW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- KJRCEJOSASVSRA-UHFFFAOYSA-N propane-2-thiol Chemical compound CC(C)S KJRCEJOSASVSRA-UHFFFAOYSA-N 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KVKODFTYVJHYLV-UHFFFAOYSA-M 1-(4-ethoxypyrimidin-2-yl)-8-(ethyldisulfanyl)quinolin-1-ium;chloride Chemical compound [Cl-].CCOC1=CC=NC([N+]=2C3=C(SSCC)C=CC=C3C=CC=2)=N1 KVKODFTYVJHYLV-UHFFFAOYSA-M 0.000 description 1
- GQSFNWKUKIMOMU-UHFFFAOYSA-M 1-(4-ethoxypyrimidin-2-yl)-8-(propan-2-yldisulfanyl)quinolin-1-ium;chloride Chemical compound [Cl-].CCOC1=CC=NC([N+]=2C3=C(SSC(C)C)C=CC=C3C=CC=2)=N1 GQSFNWKUKIMOMU-UHFFFAOYSA-M 0.000 description 1
- HBDKFZNDMVLSHM-UHFFFAOYSA-N 2-(pyridin-2-ylmethylsulfinyl)-1h-benzimidazole Chemical class N=1C2=CC=CC=C2NC=1S(=O)CC1=CC=CC=N1 HBDKFZNDMVLSHM-UHFFFAOYSA-N 0.000 description 1
- 150000005695 2-halopyrimidines Chemical class 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 101150056637 Hrh2 gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MHTSJSRDFXZFHQ-UHFFFAOYSA-N quinoline-8-thiol Chemical class C1=CN=C2C(S)=CC=CC2=C1 MHTSJSRDFXZFHQ-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- WMXCDAVJEZZYLT-UHFFFAOYSA-N tert-butylthiol Chemical compound CC(C)(C)S WMXCDAVJEZZYLT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22116788 | 1988-07-19 | ||
| US07/221,167 US4859679A (en) | 1988-07-19 | 1988-07-19 | Antiulcer (alkyldithio) quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK171988B1 true DK171988B1 (da) | 1997-09-08 |
Family
ID=22826644
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK354089D DK171988B1 (da) | 1988-07-19 | 1989-07-18 | Kvaternære 8-(alkyldithio)-1-(2-pyrimidyl)quinoliniumsalte |
| DK354089A DK354089A (da) | 1988-07-19 | 1989-07-18 | Kvaternaere 8-(alkyldithio)-1(2-pyrimidyl) quinoliniumsalte |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK354089A DK354089A (da) | 1988-07-19 | 1989-07-18 | Kvaternaere 8-(alkyldithio)-1(2-pyrimidyl) quinoliniumsalte |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4859679A (ja) |
| EP (1) | EP0352005B1 (ja) |
| JP (1) | JPH0639471B2 (ja) |
| AT (1) | ATE98959T1 (ja) |
| CA (1) | CA1317953C (ja) |
| DE (1) | DE68911610T2 (ja) |
| DK (2) | DK171988B1 (ja) |
| ES (1) | ES2062000T3 (ja) |
| FI (1) | FI91755C (ja) |
| IE (1) | IE61467B1 (ja) |
| PT (1) | PT91198B (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4037003A1 (de) * | 1990-05-30 | 1991-12-05 | Bayer Ag | Substituierte azine |
| US5177079A (en) * | 1991-01-31 | 1993-01-05 | Warner-Lambert Company | 2-substituted-4,6-di-tertiarybutyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents |
| EP0569493A4 (en) * | 1991-01-31 | 1993-11-24 | Warner-Lambert Company | Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines |
| US5270319A (en) * | 1991-09-09 | 1993-12-14 | Warner-Lambert Company | 5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents |
| US5220025A (en) * | 1992-02-24 | 1993-06-15 | Warner-Lambert Company | 2-substituted amino-4, 6-di-tertiary-butyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents |
| US5196431A (en) * | 1992-02-24 | 1993-03-23 | Warner-Lambert Company | 2-substituted amino-4, 6-di-tertiary-buthyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents |
| CA2094465A1 (en) * | 1992-04-23 | 1993-10-24 | Pierre Andre Raymond Bruneau | Cycloalkane derivatives |
| US7354309B2 (en) * | 2005-11-30 | 2008-04-08 | John Mezzalingua Associates, Inc. | Nut seal assembly for coaxial cable system components |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4673677A (en) * | 1983-10-03 | 1987-06-16 | Pfizer Inc. | Method for treatment of gastrointestinal disorders |
| DK337086A (da) * | 1985-08-12 | 1987-02-13 | Hoffmann La Roche | Benzimidazolderivater |
| DE3773240D1 (de) * | 1986-03-28 | 1991-10-31 | Otsuka Pharma Co Ltd | Hydrochinolinverbindungen, diese enthaltende zusammensetzungen und verfahren zu ihrer herstellung. |
| US4808591A (en) * | 1988-02-16 | 1989-02-28 | Pfizer Inc. | Antiulcer 8-(2-pyrimidylsulfinyl)quinolines |
-
1988
- 1988-07-19 US US07/221,167 patent/US4859679A/en not_active Expired - Fee Related
-
1989
- 1989-07-11 AT AT89307039T patent/ATE98959T1/de not_active IP Right Cessation
- 1989-07-11 EP EP89307039A patent/EP0352005B1/en not_active Expired - Lifetime
- 1989-07-11 ES ES89307039T patent/ES2062000T3/es not_active Expired - Lifetime
- 1989-07-11 DE DE89307039T patent/DE68911610T2/de not_active Expired - Fee Related
- 1989-07-17 JP JP1184389A patent/JPH0639471B2/ja not_active Expired - Lifetime
- 1989-07-17 CA CA000605906A patent/CA1317953C/en not_active Expired - Fee Related
- 1989-07-18 FI FI893471A patent/FI91755C/fi not_active IP Right Cessation
- 1989-07-18 PT PT91198A patent/PT91198B/pt not_active IP Right Cessation
- 1989-07-18 DK DK354089D patent/DK171988B1/da active
- 1989-07-18 DK DK354089A patent/DK354089A/da unknown
- 1989-07-18 IE IE231689A patent/IE61467B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE98959T1 (de) | 1994-01-15 |
| EP0352005A2 (en) | 1990-01-24 |
| JPH0273081A (ja) | 1990-03-13 |
| FI893471A0 (fi) | 1989-07-18 |
| FI91755C (fi) | 1994-08-10 |
| PT91198A (pt) | 1990-02-08 |
| ES2062000T3 (es) | 1994-12-16 |
| IE892316L (en) | 1990-01-19 |
| US4859679A (en) | 1989-08-22 |
| FI91755B (fi) | 1994-04-29 |
| FI893471A (fi) | 1990-01-20 |
| JPH0639471B2 (ja) | 1994-05-25 |
| PT91198B (pt) | 1995-03-01 |
| DE68911610D1 (de) | 1994-02-03 |
| DE68911610T2 (de) | 1994-04-07 |
| EP0352005B1 (en) | 1993-12-22 |
| IE61467B1 (en) | 1994-11-02 |
| DK354089A (da) | 1990-01-22 |
| CA1317953C (en) | 1993-05-18 |
| DK354089D0 (da) | 1989-07-18 |
| EP0352005A3 (en) | 1990-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5703097A (en) | 5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazole derivatives | |
| US8288382B2 (en) | Diaminothiazoles useful as Axl inhibitors | |
| KR100472126B1 (ko) | 양성자 펌프 억제제의 프로드러그 | |
| EP2114955A1 (en) | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors | |
| EA023998B1 (ru) | Аминохинолины в качестве ингибиторов киназ | |
| KR20010101699A (ko) | (ｓ)-오메프라졸의 칼륨염 | |
| DK171988B1 (da) | Kvaternære 8-(alkyldithio)-1-(2-pyrimidyl)quinoliniumsalte | |
| CS241074B2 (en) | Method of thiazolidine derivatives preparation | |
| ZA200510221B (en) | Process for preparing isomerically pure prodrugs of proton pump inhibitors | |
| EP0116769A1 (en) | Dihydropyridines | |
| RU2139286C1 (ru) | Замещенные арилалкилтиоалкилтиопиридины для борьбы с бактериями helicobacter | |
| CA2275601A1 (en) | Imidazopyridazines | |
| US4808591A (en) | Antiulcer 8-(2-pyrimidylsulfinyl)quinolines | |
| EP0452076B1 (en) | Thiazole and imidazole derivatives and antiulcer composition containing same | |
| RU2154062C2 (ru) | Замещенные арилтиоалкилтиопиридины, способ их получения, лекарственное средство на их основе и способ получения лекарственного средства. | |
| HU188742B (en) | Process for producing substituted 3,4-diamni-1,2,5-thiadiazoles and pharmaceutical compositions of hystamine-h2-receptor antagonistic aczivity containing them as active agents | |
| US4742055A (en) | 3- and 5-amino thiatriazines, and their pharmaceutical uses | |
| RU2232159C2 (ru) | Производные бензимидазола и фармацевтические композиции, содержащие пролекарство ингибитора протонного насоса | |
| JPH10505328A (ja) | ヘリコバクター細菌類を撲滅するためのピペラジノチオピリジン | |
| KR880002530B1 (ko) | 치환된 에탄디이미드 아미드 및 그의 제조방법 | |
| JPH1036367A (ja) | ピリジン化合物 | |
| JPH0449555B2 (ja) | ||
| IE42408B1 (en) | Novel amidine compounds | |
| CZ2001457A3 (cs) | Proléčiva inhibitorů protonové pumpy |